Arcutis Biotherapeutics Azioni (NASDAQ: ARQT)

Ultime notizie per Arcutis Biotherapeutics (NASDAQ:ARQT) Azioni

Arcutis Biotherapeutics

Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.

Arcutis Biotherapeutics, Inc. - Common stock

Arcutis Biotherapeutics Inc

Sportradar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRAD#NASDAQ">SRAD</a>) today announced the launch of generative AI (gen AI) audio, a new feature within its ad:s multi-channel marketing service. The tool leverages the power of gen AI integrated with Sportradar's live data, to automate the creation of personalized, real-time audio adverts for sportsbook and casino operators across one of the fastest growing digital marketing channels globally.
Ad:s gen AI audio provides operators with a ready-to-use audio marketing solution, allowing them to generate creative content during key sporting and gaming moments to efficiently scale advertising efforts into podcast streaming services and internet radio networks. Sportradar's industry-leading technology automatically creates customised and dynamic adverts – featuring live-data to update odds, jackpots, and upcoming events— to increase brand awareness, uplift purchase intent and increase the likelihood of customer acquisition.
AI-generated audio adverts are the latest addition to Sportradar's comprehensive, industry-leading, end-to-end marketing services, driving brand awareness, acquisition and retention across channels including programmatic display, video, audio, digital-out-of-home (DOOH), paid social media, paid search, sponsorships and affiliate marketing.
Niki Beier, SVP Marketing Services, said: "Sports fans and bettors are increasingly consuming audio content, with listenership increasing by over 1000% in the past seven years1. To deliver maximum marketing efficiency, we're providing a sophisticated yet simple-to-use solution to sportsbook and casino operators. Through our gen AI technology, we're making it easy for clients to integrate audio adverts into their acquisition and branding campaigns, to reach more customers with real-time relevant audio messages, without the need for creative teams or a high production budget."

News

SRAD

Sportradar Launches Gen AI Audio Ads for Real-Time Sportsbook Marketing

Earnings

NIPG

NIP Group Reported H1 Revenue Of $39.34M Vs $38.56M YoY, EPS Loss Of $(1.04) Vs $(0.71) YoY

Macro Economic Events

Econ #s

Economics

Germany Ifo Business Climate Index For November 85.7 Vs. 86.1 Est.; 86.5 Prior

Germany Current Assessment For November 84.3 Vs. 85.4 Est.; 85.7 Prior

Germany Business Expectations For November 87.2 Vs. 87.0 Est.; 87.3 Prior

VivoPower International PLC (Nasdaq: "VVPR") (the "Company" or "VivoPower") is on track to file its Annual Report on Form 20-F for the fiscal year ending June 30, 2024, no later than November 29, 2024, in compliance with NASDAQ's filing requirements.
The delay in filing the Form 20-F has been primarily due to significant strategic changes, including the sale of the Aevitas critical power businesses, the business combination agreement involving Tembo e-LV B.V. and Cactus Acquisition Corp. 1 Ltd., and other previously announced updates. Additionally, the Company's management and auditors have been focussed on completing the audited accounts for Tembo e-LV B.V. ("Tembo"), a subsidiary of VivoPower, which are required to be included in the Registration Statement on Form F-4 to be filed in connection with Tembo's business combination with Cactus Acquisition Corp. 1 Ltd.
VivoPower anticipates filing the Form 20-F no later than November 29, 2024.
Upon filing the Form 20-F Annual Report, the Company will be able to proceed with its annual shareholder update call. Details of the call will be provided separately and will be available on the Company's website. VivoPower aims to release this information before Friday, December 6, 2024.

Government

Regulations

VVPR

VivoPower Targets November 29 for Form 20-F Filing Amid Strategic Changes and Tembo Business Updates, Prepares for Shareholder Update Call in December

Edwards Lifesciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) today announced one-year data highlighting the continued outstanding performance of its SAPIEN 3 Ultra RESILIA valve. The data were presented at PCR London Valves 2024 and simultaneously published in the Journal of the American College of Cardiology (JACC): Cardiovascular Interventions.
An analysis of data from more than 9,000 propensity-matched patients in the STS/ACC TVT Registry1 demonstrated that those who received Edwards' newest generation SAPIEN 3 Ultra RESILIA valve experienced outstanding one-year outcomes that continuously surpassed recipients of the earlier generation SAPIEN 3 and SAPIEN 3 Ultra valves. Patients receiving the SAPIEN 3 Ultra RESILIA valve experienced extremely low mortality, low rates of reintervention, larger effective orifice areas, lower echo-derived gradients across all valve sizes and no paravalvular leak in 84.4% of cases.
"These strong, real-world data continue to demonstrate that patients treated with a SAPIEN valve experience excellent outcomes with rapid recovery and improved quality of life," said Larry Wood, Edwards' corporate vice president and group president, transcatheter aortic valve replacement and surgical structural heart. "These data add to the immense body of evidence with multiple years of follow up on the Edwards SAPIEN valve platform and more than 10 years of clinical experience with the RESILIA tissue."
Patients in the SAPIEN 3 Ultra RESILIA valve cohort, who had an average STS score of 3.6 and average age of 77, experienced meaningful quality of life benefits with a clinically significant average 31-point increase in KCCQ2 score and one-day length of hospital stay with 93% discharged to their homes.
"This is the first large-population study that showed the latest generation SAPIEN 3 Ultra RESILIA valve results in improved 1-year survival after TAVR versus prior generation valves, given it reduces mild or greater paravalvular leak," said Gilbert Tang, MD, MSc, MBA, Surgical and Academic Director of the Structural Heart Program for the Mount Sinai Health System and Professor and Vice-Chair of Innovation in Cardiovascular Surgery at the Icahn School of Medicine at Mount Sinai. "This finding particularly affected low surgical risk patients, where the impact would matter more because of their longer life expectancies."
Dr. Tang is a consultant for Edwards Lifesciences. 1 The STS/ACC TVT Registry is a collaboration between the Society of Thoracic Surgeons (STS) and the American College of Cardiology (ACC). 2 The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a 23-item survey that measures the impact of heart failure on a patient's quality of life, symptoms, and physical function.

Edwards Lifesciences' SAPIEN 3 Ultra RESILIA Valve Shows One-Year Outcomes: Data Presented at PCR London Valves

Highlights for the Quarter Ended September 30, 2024
<ul>
<li>Transaction volume was 7,046 units for the three months ended September 30, 2024, an increase of 25.7% from 5,605 units in the last quarter and an increase of 81.4% from 3,884 units in the same period last year.</li>
<li>Retail transaction volume was 6,005 units, an increase of 46.8% from 4,090&nbsp;units in the last quarter and an increase of 162.6% from 2,287 units in the same period last year.</li>
</ul>

UXIN

Uxin Limited Reported Q2 Transaction Volume Of 7,046 Units, Up 81.4% YoY, Retail Transaction Volume Of 6,005 Units, Up By 162.6% YoY

Business Outlook
For the three months ending December 31, 2024, the Company expects its retail transaction volume to be within the range of 7,800 units to 8,100 units. The Company estimates that its total revenues including retail vehicle sales revenue, wholesale vehicle sales revenue and other revenue to be within the range of RMB560 million to RMB580 million. The Company expects its Non-GAAP adjusted EBITDA to be positive. These forecasts reflect the Company's current and preliminary views on the market and operational conditions, which are subject to changes.

Guidance

Uxin Limited Expects Q3 Revenue Of RMB560M-RMB580M, Positive Adj EBITDA

Uxin Q2 Sales $70.85M Up From $48.80M YoY

<h3>Companies Reporting Before The Bell</h3>
• Alarum Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAR#NASDAQ">ALAR</a>) is likely to report quarterly earnings at $0.04 per share on revenue of $7.00 million. 
• BioLine Rx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) is expected to report quarterly loss at $0.10 per share on revenue of $4.12 million. 
• Uxin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UXIN#NASDAQ">UXIN</a>) is estimated to report earnings for its second quarter. 
• Super Hi International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HDL#NASDAQ">HDL</a>) is expected to report quarterly earnings at $0.21 per share on revenue of $227.49 million. 
• Diana Shipping (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DSX#NYSE">DSX</a>) is estimated to report quarterly earnings at $0.09 per share on revenue of $68.00 million. 
• Bath &amp; Body Works (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBWI#NYSE">BBWI</a>) is expected to report quarterly earnings at $0.47 per share on revenue of $1.58 billion. 
• Freightos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRGO#NASDAQ">CRGO</a>) is expected to report quarterly loss at $0.16 per share on revenue of $5.95 million. 
<h3>Companies Reporting After The Bell</h3>
• BBB Foods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TBBB#NYSE">TBBB</a>) is estimated to report quarterly earnings at $0.03 per share on revenue of $776.51 million. 
• Agilent Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/A#NYSE">A</a>) is estimated to report quarterly earnings at $1.40 per share on revenue of $1.67 billion. 
• Central Garden &amp; Pet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENTA#NASDAQ">CENTA</a>) is likely to report quarterly loss at $0.22 per share on revenue of $706.77 million. 
• Central Garden &amp; Pet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENT#NASDAQ">CENT</a>) is projected to report quarterly loss at $0.20 per share on revenue of $707.30 million. 
• LexinFintech Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LX#NASDAQ">LX</a>) is estimated to report earnings for its third quarter. 
• Hesai Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSAI#NASDAQ">HSAI</a>) is projected to report quarterly loss at $0.02 per share on revenue of $69.82 million. 
• Leslies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LESL#NASDAQ">LESL</a>) is projected to report quarterly earnings at $0.11 per share on revenue of $404.09 million. 
• Semtech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTC#NASDAQ">SMTC</a>) is estimated to report quarterly earnings at $0.23 per share on revenue of $232.90 million. 
• Agora (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/API#NASDAQ">API</a>) is estimated to report quarterly loss at $0.04 per share on revenue of $40.00 million. 
• Fluence Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLNC#NASDAQ">FLNC</a>) is estimated to report quarterly earnings at $0.30 per share on revenue of $1.31 billion. 
• Zoom Video Comms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZM#NASDAQ">ZM</a>) is expected to report quarterly earnings at $1.31 per share on revenue of $1.16 billion. 
• Woodward (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WWD#NASDAQ">WWD</a>) is likely to report quarterly earnings at $1.25 per share on revenue of $812.95 million. 
• Blue Bird (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLBD#NASDAQ">BLBD</a>) is expected to report quarterly earnings at $0.67 per share on revenue of $324.70 million. 
• Grupo Supervielle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUPV#NYSE">SUPV</a>) is estimated to report quarterly earnings at $0.20 per share on revenue of $199.08 million. 
• New Jersey Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NJR#NYSE">NJR</a>) is projected to report quarterly earnings at $0.88 per share on revenue of $407.00 million. 
• Pennant Park Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNNT#NYSE">PNNT</a>) is expected to report quarterly earnings at $0.22 per share on revenue of $36.14 million. 
• PennantPark Floating Rate (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFLT#NYSE">PFLT</a>) is projected to report quarterly earnings at $0.32 per share on revenue of $48.95 million. 
• Enanta Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>) is likely to report quarterly loss at $1.16 per share on revenue of $17.93 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALAR

BBWI

BLBD

BLRX

CENT

CENTA

CRGO

ENTA

FLNC

HSAI

LESL

PFLT

PNNT

SMTC

SUPV

TBBB

Earnings Scheduled For November 25, 2024

President-elect Donald Trump&#8217;s pick for Commerce Secretary, Howard Lutnick, is in the process of forging a multi-billion dollar deal with Tether (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">USDT</a>), the company behind the world&#8217;s largest stablecoin by market capitalization.
What happened: Cantor Fitzgerald, a financial services firm led by Lutnick, is planning to launch a program with Tether&#8217;s support that would lend dollars to clients who pledged Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) as collateral, according <a href="https://www.bloomberg.com/news/articles/2024-11-24/lutnick-s-cantor-in-talks-with-tether-about-bitcoin-lending-program-usdt">to</a> a Bloomberg, citing sources familiar with the matter.
The funding for the program is expected to start at $2 billion, eventually running up to &#8220;tens of billions.&#8221;
Both Cantor and Tether didn&#8217;t immediately return <a href="https://pro.benzinga.com/dashboard">Benzinga&#8217;s</a> request to confirm the report.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">&#x1f602;&#x1f4af; <a href="https://t.co/PzkLsmVFz7">https://t.co/PzkLsmVFz7</a>
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1860470986438545485?ref_src=twsrc%5Etfw">November 23, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42155055/crypto-analyst-bitcoin-poised-to-skyrocket-to-180k-and-eventually-top-1m">Crypto Analyst: Bitcoin Poised To Skyrocket To $180K and &#8216;Eventually&#8217; Top $1M</a>
Why It Matters: Cantor has been Tether&#8217;s Wall Street banker, <a href="https://www.benzinga.com/markets/cryptocurrency/24/08/40423424/donald-trump-names-howard-lutnick-to-lead-transition-team-heres-what-it-means-for-crypto">acting as the custodian</a> of billions of dollars of U.S. Treasuries that back the USDT stablecoin.
In the past, Lutnick praised Tether, stating that the company had sufficient reserves.
&#8220;I manage many, many of their assets. From what we've seen, and we did a lot of work, they have the money,&#8221; he <a href="https://www.benzinga.com/markets/cryptocurrency/24/01/36647873/tether-has-the-money-says-billionaire-ceo-bitcoin-will-grow">said in an interview</a>.
Lutnick&#8217;s support and his elevation to a top cabinet post come amid controversy surrounding Tether, which has been accused of <a href="https://www.benzinga.com/markets/cryptocurrency/24/01/36644909/from-casinos-to-slaves-un-report-details-tethers-role-in-organized-crime">aiding criminal activities </a>like illegal gambling and money laundering.
A report last month also <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41555467/federal-probe-into-tether-examines-potential-sanctions-and-money-laundering-breaches-wsj">pointed toward a federal probe</a> into possible misuse of Tether&#8217;s stablecoin in illegal activities. Tether CEO&nbsp;Paolo Ardoino, however, denied being under any investigation.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42154900/crypto-expert-who-called-2022-market-crash-warns-about-bitcoin">Crypto Expert Who Called 2022 Market Crash Warns About Bitcoin</a></li>
</ul>
Photo courtesy: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

$BTC

$USDT

Trump's Commerce Secretary Pick Howard Lutnick-Led Firm In Talks For A Bitcoin Lending Project With Tether: Report

Zoom Video Communications, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZM#NASDAQ">ZM</a>) will release earnings results for its third quarter, after the <a href="https://www.benzinga.com/quote/ZM/earnings">closing bell on Monday, Nov. 25.</a>
Analysts expect the San Jose, California-based bank to report quarterly earnings at $1.31 per share, up from $1.29 per share in the year-ago period. Zoom Video projects to report revenue of $1.16 billion for the recent quarter, compared to $1.14 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Aug. 21, Zoom reported quarterly earnings of $1.39 per share which beat the analyst consensus estimate of $1.21 by 14.88%. Quarterly revenue of $1.16 billion also beat the consensus estimate and is a 2.09% increase from the same period last year.
Zoom Video shares gained 5.8% to close at $85.88 on Friday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/TCOM/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/585aa876b5a482000151d0ed/catharine-trebnick">Rosenblatt analyst Catharine Trebnick</a> maintained a Buy rating with a price target of $78 on Nov. 22. This analyst has an accuracy rate of 73%.</li>
<li>Morgan Stanley analyst Meta Marshall maintained an Equal-Weight rating and raised the price target from $68 to $86 on Nov. 13. This analyst has an accuracy rate of 73%.</li>
<li><a href="https://www.benzinga.com/topic/daniel-ives">Wedbush analyst Daniel Ives</a> upgraded the stock from Neutral to Outperform and increased the price target from $80 to $85 on Oct. 17. This analyst has an accuracy rate of 79%.</li>
<li>Deutsche Bank analyst Matthew Niknam maintained a Hold rating and increased the price target from $71 to $75 on Aug. 23. This analyst has an accuracy rate of 64%.</li>
<li>Baird analyst William Power maintained an Outperform rating and cut the price target from $84 to $77 on Aug. 22. This analyst has an accuracy rate of 85%.</li>
</ul>
Considering buying ZM stock? Here&#8217;s what analysts think:
Read This Next:
<ul>
<li> <a href="https://www.benzinga.com/24/11/42137942/jim-cramer-says-this-stock-is-a-bitcoin-play-and-he-prefers-to-own-bitcoin">Jim Cramer Says This Stock Is A Bitcoin Play And He Prefers To Own Bitcoin</a></li>
</ul>

Price Target

Analyst Ratings

Trading Ideas

Zoom Video Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Elon Musk, Donald Trump&#8216;s pick to co-lead the Department of Government Efficiency (DOGE), has voiced strong criticism against the F-35 stealth fighter program, advocating for the use of drones over manned jets.
What Happened: On Sunday, Musk shared a video on his social media platform X, featuring synchronized drone swarms, and remarked, "Meanwhile, some idiots are still building manned fighter jets like the F-35.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Meanwhile, some idiots are still building manned fighter jets like the F-35 &#x1f5d1;&#xFE0F; &#x1fae0; <a href="https://t.co/4JX27qcxz1">pic.twitter.com/4JX27qcxz1</a>
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1860574377013838033?ref_src=twsrc%5Etfw">November 24, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The Pentagon&#8217;s joint program office defended the F-35, highlighting its preference among U.S. Services and international partners. A spokesperson emphasized its effectiveness and growing global interest.&nbsp;Lockheed Martin&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>), the main contractor, expressed its commitment to collaborating&nbsp;with the new administration and&nbsp;praised the F-35&#8217;s capabilities, Fortune<a href="https://fortune.com/2024/11/24/elon-musk-f35-stealth-fighter-drones-pentagon-weapons-doge-lockheed/"> reported</a> on Monday.
Despite Musk&#8217;s criticism, the Pentagon continues to operate&nbsp;a mix of manned and&nbsp;unmanned aircraft. The F-35 program, awarded to Lockheed in 2001, has faced scrutiny for cost overruns and delays. The Defense Department&#8217;s estimate for the program&#8217;s total cost is&nbsp;$1.8 trillion, making it the&nbsp;most expensive in its history.
See Also:&nbsp;<a href="https://www.benzinga.com/24/11/42140065/with-musk-and-ramaswamy-preparing-to-slash-entire-government-agencies-heres-which-departments-employ-the-most-americans-and-their-salaries?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">With Musk And Ramaswamy Preparing To Slash Entire Government Agencies, Here&#8217;s Which Departments Employ The Most Americans And Their Salaries</a>
Why It Matters: Musk&#8217;s recent criticism aligns with his ongoing concerns <a href="https://www.benzinga.com/government/24/09/40868796/musk-criticizes-governments-fiscal-policy-says-extreme-government-overspending-is-bankrupting-americ">about government spending</a>. Back in September, Musk criticized the U.S. government&#8217;s fiscal policy, warning that &#8220;extreme government overspending is bankrupting America&#8221; and contributing to inflation. He expressed these concerns on X, highlighting the potential financial risks of unchecked spending.
President-elect Donald Trump appointed the Department of Government Efficiency (DOGE) to tackle wasteful spending. However, analysts like Mario Georgiou of InCred Global Wealth U.K. predict only a modest impact, estimating potential savings of $50–100 billion annually, according to the&nbsp;<a href="https://www.benzinga.com/24/11/42131911/donald-trump-appointed-doge-to-have-marginal-impact-saving-50-100-billion-says-analyst-as-elon-musk-aims-to-target-500-billion-plus-in-federal-expenditures">Congressional Budget Office</a>. This figure pales in comparison to the total federal outlays of approximately $6.7 trillion projected for 2024.
Musk&#8217;s critique of the F-35 program is part of a broader conversation about fiscal responsibility and the need to reassess costly government programs. 
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/etfs/24/11/42044642/trump-appears-frustrated-as-elon-musk-chimes-in-on-treasury-secretary-adds-more-names-to-a-list-of-potential-picks?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Trump Appears &#8216;Frustrated&#8217; As Elon Musk Chimes In On Treasury Secretary, Adds More Names To Short List</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Image via Flickr

General

Trump's DOGE Co-Lead Elon Musk Slams Lockheed Martin's F-35 Fighter Jets, Advocates Drone Warfare As Pentagon Defends $1.8 Trillion Program

El Salvador president Nayib Bukele floated the idea of a &#8220;rent your volcano to mine Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)&#8221; policy in the wake of the country&#8217;s successful geothermal-powered mining venture.
What Happened: On Sunday, Bukele took to X to share the success of El Salvador&#8217;s Bitcoin mining venture. He suggested that, given the nation&#8217;s abundant geothermal power potential, a business policy of renting volcanoes to mine Bitcoin might &#8220;make sense.&#8221; 
Bukele was reacting to another X user&#8217;s post on the country&#8217;s stockpile of 474 Bitcoins mined with geothermal power, which swelled to $46 million due to the leading cryptocurrency&#8217;s ongoing bull run.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">And with 170 volcanoes&#8230; ⁰A "rent your volcano to mine Bitcoin" program might actually make sense &#x1f914; <a href="https://t.co/BENtEqher1">https://t.co/BENtEqher1</a>
&mdash; Nayib Bukele (@nayibbukele) <a href="https://twitter.com/nayibbukele/status/1860831169463386465?ref_src=twsrc%5Etfw">November 24, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also:&nbsp;<a href="https://www.benzinga.com/24/11/42156261/are-microstrategys-shares-worth-only-105-investment-adviser-gary-black-weighs-in">Are MicroStrategy&#8217;s Shares Worth Only $105? Investment Adviser Gary Black Weighs In</a>
Why It Matters: El Salvador&#8217;s plan to tap its geothermal power led to the idea of the <a href="https://www.benzinga.com/markets/cryptocurrency/24/08/40330518/nayib-bukeles-bitcoin-city-project-in-el-salvador-attracts-1-6b-investment-from-turkey-bas">ambitious Bitcoin City project</a>. 
The city, located near a volcano, is expected to be powered by geothermal energy, exempting all of its activities, including Bitcoin mining, from all taxes except for the value-added tax. It is&nbsp;planned to be a full-fledged metropolis, complete with residential and commercial areas, restaurants, an airport, and a port and rail service.&nbsp;
To finance the development of the city, El Salvador even introduced a <a href="https://www.benzinga.com/markets/cryptocurrency/23/12/36192059/el-salvadors-volcanic-bitcoin-bond-approval-sets-stage-to-build-a-crypto-city">&#8220;Volcano Bond</a>,&#8221; also called a Bitcoin-backed bond. 
El Salvador, the first nation to adopt Bitcoin as a legal tender, has been strategically investing in the cryptocurrency under Bukele&#8217;s leadership.
As of this writing, El Salvador <a href="https://bitcoin.gob.sv/">holds </a>5,944.77 Bitcoins in its treasury, worth more than $583 million at current market prices.
Price Action: At the time of writing, Bitcoin was exchanging hands at $98,122.26, down 0.20% in the last 24 hours, according to <a href="https://pro.benzinga.com/dashboard?_gl=1&#x2A;380nj0&#x2A;_ga&#x2A;MTEyOTAyOTcxMy4xNzEzMzY0NTYy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDk4MzIzMi42LjEuMTcxNDk4OTE0Ni4wLjAuMA.." target="_blank" rel="noreferrer noopener">data from Benzinga Pro</a>.  Photo by Gobierno Danilo Medina on Flickr
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42155055/crypto-analyst-bitcoin-poised-to-skyrocket-to-180k-and-eventually-top-1m">Crypto Analyst: Bitcoin Poised To Skyrocket To $180K and &#8216;Eventually&#8217; Top $1M</a></li>
</ul>

El Salvador's President Nayib Bukele Says Renting Out Volcanoes To Mine Bitcoin May 'Actually Make Sense'

The CNN Money Fear and Greed index showed further improvement in the overall market sentiment, while the index remained in the &#8220;Greed&#8221; zone on Friday.
U.S. stocks settled higher on Friday, with the Dow Jones index closing at a fresh record level during the session.
Major indices on Wall Street recorded gains last week, with the Dow gaining around 2% and the S&amp;P 500 adding around 1.7%.
Ross Stores (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROST#NASDAQ">ROST</a>) shares gained 2% on Friday after the company reported better-than-expected third-quarter EPS results. Elastic N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESTC#NYSE">ESTC</a>) shares jumped around 15% after the company reported better-than-expected second-quarter financial results and issued FY25 guidance above estimates.
On the economic data front, the S&amp;P Global US Services PMI climbed to 57 in November versus 55 in the previous month, while manufacturing PMI increased to 48.8 in November from 48.5 in the previous month. The University of Michigan consumer sentiment for the US fell to 71.8 in November versus a preliminary reading of 73.
Most sectors on the S&amp;P 500 closed on a positive note, with industrials, financials, and consumer discretionary stocks recording the biggest gains on Friday. However, utilities and communication services stocks bucked the overall market trend, closing the session lower.
The Dow Jones closed higher by around 426 points to 44,296.51 on Friday. The S&amp;P 500 rose 0.35% to 5,969.34, while the Nasdaq Composite rose 0.16% to close at 19,003.65 during Friday's session.
Investors are awaiting earnings results from Bath &amp; Body Works, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBWI#NYSE">BBWI</a>), Agilent Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/A#NYSE">A</a>), and Zoom Video Communications, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZM#NASDAQ">ZM</a>) today.
What is CNN Business Fear &amp; Greed Index?
At a current reading of 60.9, the index remained in the &#8220;Greed&#8221; zone on Friday, versus a prior reading of 57.7.
The Fear &amp; Greed Index is a measure of the current market sentiment. It is based on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42137942/jim-cramer-says-this-stock-is-a-bitcoin-play-and-he-prefers-to-own-bitcoin">Jim Cramer Says This Stock Is A Bitcoin Play And He Prefers To Own Bitcoin</a></li>
</ul>
Photo courtesy: Shutterstock

Long Ideas

Pre-Market Outlook

ESTC

ROST

Dow Settles At Record High As Investor Sentiment Improves: Fear Index Remains In 'Greed' Zone

ELAB

Elevai Labs Implements 1-for-200 Reverse Stock Split tT Retain Nasdaq Listing, Reduces Shares To 3.07M

BURU

Reported Friday, NUBURU Receives NYSE Notice For Non-Compliance, Must Address Audit Committee Shortfall By January 2025

With U.S. stock futures trading higher this morning on Monday, some of the stocks that may grab investor focus today are as follows:
<ul>
<li>Wall Street expects Bath &amp; Body Works, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBWI#NYSE">BBWI</a>) to report quarterly earnings at 47 cents per share on revenue of $1.58 billion before the opening bell, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. Bath &amp; Body Works shares rose 2.6% to $31.51 in after-hours trading.</li>
<li>Analysts are expecting Agilent Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/A#NYSE">A</a>) to post quarterly earnings at $1.41 per share on revenue of $1.67 billion. The company will release earnings after the markets close. Agilent shares gained 0.8% to $134.96 in after-hours trading.</li>
<li>Silexion Therapeutics Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLXN#NASDAQ">SLXN</a>) reported a 1-for-9 reverse share split. Silexion Therapeutics shares dipped 11.2% to $0.2725 in the after-hours trading session.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<ul>
<li>After the markets close, Woodward, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WWD#NASDAQ">WWD</a>) is projected to post quarterly earnings at $1.26 per share on revenue of $811.01 million. Woodward shares rose 0.3% to $176.49 in after-hours trading.</li>
<li>Analysts expect Zoom Video Communications, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZM#NASDAQ">ZM</a>) to report quarterly earnings at $1.31 per share on revenue of $1.16 billion after the closing bell. Zoom Video shares gained 1.3% to $86.95 in after-hours trading.</li>
</ul>
Check This Out:<a href="https://www.benzinga.com/24/11/42137942/jim-cramer-says-this-stock-is-a-bitcoin-play-and-he-prefers-to-own-bitcoin"> </a>
<ul>
<li><a href="https://www.benzinga.com/24/11/42137942/jim-cramer-says-this-stock-is-a-bitcoin-play-and-he-prefers-to-own-bitcoin">Jim Cramer Says This Stock Is A Bitcoin Play And He Prefers To Own Bitcoin</a></li>
</ul>
Photo courtesy: Shutterstock

SLXN

Agilent, Bath & Body Works And 3 Stocks To Watch Heading Into Monday

<ul>
<li>Attruby is the first and only approved product with a label specifying near-complete stabilization of TTR. Attruby has been shown to preserve the native function of TTR as a transport protein of thyroxine and vitamin A and to demonstrate benefit on cardiovascular outcomes</li>
<li>Attruby demonstrated the most rapid benefit seen in any Phase 3 study of ATTR-CM to date:</li>
<li>In as few as 3 months, the time to first event (all-cause mortality (ACM) or cardiovascular-related hospitalizations (CVH)) durably separated relative to placebo</li>
<li>A 42% reduction in composite ACM and recurrent CVH events relative to placebo at Month 30</li>
<li>A 50% reduction in the cumulative frequency of CVH events relative to placebo at Month 30</li>
<li>To honor the courage of our U.S. clinical trial participants, BridgeBio will provide these patients Attruby free for life</li>
<li>To learn about our extensive suite of programs to provide access to Attruby call 1-888-55-BRIDGE (1-888-552-7434)</li>
<li>With this approval, BridgeBio will receive a $500 million payment under our royalty funding agreement</li>
</ul>

BBIO

Reported Friday, BridgeBio's Attruby Earns FDA Nod As First Therapy With ≥90% TTR Stabilization, Offering Hope For ATTR-CM Patients

Arcutis Biotherapeutics (ARQT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Tyler Va...

Arcutis Biotherapeutics: Strong Commercial Execution and Strategic Growth Initiatives Justify Buy Rating

Arcutis Biotherapeutics Inc ( ($ARQT) ) has released its Q3 earnings. Here is a breakdown of the information Arcutis Biotherapeutics Inc presented ...

Arcutis Biotherapeutics Reports Strong Q3 2024 Results

Arcutis Biotherapeutics, Inc. (ARQT) Q3 2024 Earnings Call Transcript

Arcutis Biotherapeutics (ARQT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Vikram Puroh...

Strong Buy Rating for Arcutis Biotherapeutics: Impressive Q3 Performance and Promising Growth Prospects

Arcutis Biotherapeutics (ARQT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Serge Belang...

Arcutis Biotherapeutics: Strong Q3 Performance and Strategic Growth Drive Buy Rating

Mizuho Securities analyst Uy Ear has reiterated their bullish stance on ARQT stock, giving a Buy rating yesterday. Uy Ear has given his Buy rating ...

Arcutis Biotherapeutics: Strong Financial Outlook and Strategic Growth Justify Buy Rating and $19 Price Target

Arcutis Biotherapeutics: +200% On ZORYVE Approval, But When Is The Next Leg Up?

Arcutis Biotherapeutics: What Lies Ahead

Mizuho Securities analyst Uy Ear has maintained their bullish stance on ARQT stock, giving a Buy rating on November 11. Uy Ear has given his Buy ra...

Strong Prescription Growth and Competitive Advantage Drive Buy Rating for Arcutis Biotherapeutics

Arcutis Biotherapeutics: Resilient Performance and Growth Potential Amidst Short-Term Fluctuations

ARQT

Health Care

Press Releases

FDA Accepts Arcutis' Supplemental New Drug Application for ZORYVE® (roflumilast) Foam for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over

New Data Shows ZORYVE® (Roflumilast) Cream 0.15% Provided Consistent Improvement of Atopic Dermatitis in Individuals With Diverse Skin Types

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Arcutis Announces Health Canada Approval of ZORYVE® (Roflumilast) Foam 0.3% to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older

Arcutis Canada Announces Health Canada Approval of ZORYVE® Foam to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older

Arcutis to Report Third Quarter 2024 Financial Results and Participate in an Upcoming Investor Conference

Arcutis Presents Positive Patient-Reported Outcome Data for ZORYVE® (Roflumilast) Cream 0.15% in Atopic Dermatitis at American College of Allergy, Asthma and Immunology 2024 Annual Scientific Meeting

Comments

Arcutis Biotherapeutics

Notizie

Ultime notizie per Arcutis Biotherapeutics (NASDAQ:ARQT) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO